Comparison of the efficacy and safety of arformoterol 15 μg twice daily and arformoterol 30 μg once daily in COPD: A single-dose, multicenter, randomized, modified-blind, two-way crossover study

Clinical Therapeutics

Volumn 31, Issue 8, 2009, Pages 1716-1723

  Panettieri Jr , Reynold A ^a   MacIntyre, Neil ^b   Sims, Michael ^a   Kerwin, Edward ^c   Fogarty, Charles ^d   Noonan, Michael ^e   Claus, Raymond ^f   Andrews, William T ^f  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b DUKE UNIVERSITY HOSPITAL   (United States)

^c Clinical Research Institute of Southern Oregon   (United States)

^d Spartanburg Medical Research ^*  (United States)

^e Allergy Associates Research Center   (United States)

^f DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

Author keywords

bronchodilator; chronic obstructive pulmonary disease; COPD; dosing regimen; LABA; long acting 2 agonist

Indexed keywords

ARFORMOTEROL;

ADULT; ANXIETY; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSAGE SCHEDULE COMPARISON; DOSE TIME EFFECT RELATION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EVENING DOSAGE; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; INSOMNIA; MALE; MORNING DOSAGE; MULTICENTER STUDY; NEBULIZATION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION;

ADMINISTRATION, INHALATION; ADRENERGIC BETA-AGONISTS; AGED; AREA UNDER CURVE; BRONCHODILATOR AGENTS; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ETHANOLAMINES; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; LEAST-SQUARES ANALYSIS; MALE; MIDDLE AGED; NEBULIZERS AND VAPORIZERS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 72149131194     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2009.08.012     Document Type: Article

References (21)

1. Celli B.R., MacNee W., and the ATS/ ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: A summary of the ATS/ERS position paper [published correction appears in EurRespirJ. 2006; 27:242]. Eur Respir J. 23 (2004) 932-946
2. Pauwels R.A., Buist A.S., Calverley P.M., et al., the GOLD Scientific Committee. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med. 163 (2001) 1256-1276
3. Rabe K.F., Hurd S., Anzueto A., et al., the Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 176 (2007) 532-555
4. Brovana. (arformoterol tartrate) [package insert] (2006), Sepracor Inc, Marlborough, Mass
5. Dolovich M.B., Ahrens R.C., Hess D.R., et al., the American College of Chest Physicians; American College of Asthma, Allergy, and Immunology. Device selection and outcomes of aerosol therapy: Evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. Chest. 127 (2005) 335-371
6. Baumgartner R.A., Hanania N.A., Calhoun W.J., et al. Nebulized arformot-erol in patients with COPD: A 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial. Clin Ther. 29 (2007) 261-278
7. Hanrahan J.P., Hanania N.A., Calhoun W.J., et al. Effect of nebulized arformoterol on airway function in COPD: Results from two randomized trials. COPD. 5 (2008) 25-34
8. Donohue J.F., Hanania N.A., Sciarappa K.A., et al. Arformoterol and salmeterol in the treatment of chronic obstructive pulmonary disease: A one year evaluation of safety and tolerance. Ther Adv Respir Dis. 2 (2008) 37-48
9. Tashkin D.P. Multiple dose regimens. Impact on compliance. Chest. 107 Suppl (1995) 176S-182S
10. Blackwell B. Drug therapy: Patient compliance. N Engl J Med. 289 (1973) 249-252
11. Bourbeau J., and Bartlett S.J. Patient adherence in COPD. Thorax. 63 (2008) 831-838
12. George J., Kong D.C., Thoman R., and Stewart K. Factors associated with medication nonadherence in patients with COPD. Chest. 128 (2005) 3198-3204
13. Rau J.L. Determinants of patient adherence to an aerosol regimen. Respir Care. 50 (2005) 1346-1356 discussion
14. Rau J.L. Determinants of patient adherence to an aerosol regimen. Respir Care. 50 (2005) 1357-1359
15. Ingersoll K.S., and Cohen J. The impact of medication regimen factors on adherence to chronic treatment: A review of literature. J Behav Med. 31 (2008) 213-224
16. World Medical Association Declaration of Helsinki. Recommendations guiding physicians in biomedi-cal research involving human subjects. JAMA. 277 (1997) 925-926
17. Bestall J.C., Paul E.A., Garrod R., et al. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax. 54 (1999) 581-586
18. Miller M.R., Hankinson J., Brusasco V., et al., the ATS/ERS Task Force. Standardisation of spirometry. Eur Respir J. 26 (2005) 319-338
19. The European Agency for the Evaluation of Medicinal Products (EMEA), Human Medicines Evaluation Unit. ICH Topic E 9: Statistical principles for clinical trials. Step 4, consensus guideline (5 February 1998). http://www.tga.gov.au/DOCS/pdf/euguide/ich/036396en.pdf Accessed August 11, 2009
20. Redelmeier D.A., Goldstein R.S., Min S.T., and Hyland R.H. Spirometry and dyspnea in patients with COPD. When small differences mean little. Chest. 109 (1996) 1163-1168
21. Donohue J.F. Minimal clinically important differences in COPD lung function. COPD. 2 (2005) 111-124